Cargando…

Mast cell activation symptoms are prevalent in Long-COVID

OBJECTIVES: Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC. METHODS: Adults in LC-focused Facebook support groups were recruited for online...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinstock, Leonard B., Brook, Jill B., Walters, Arthur S., Goris, Ashleigh, Afrin, Lawrence B., Molderings, Gerhard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459548/ https://www.ncbi.nlm.nih.gov/pubmed/34563706 http://dx.doi.org/10.1016/j.ijid.2021.09.043

Ejemplares similares

Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
por: Afrin, Lawrence B., et al.
Publicado: (2020)

Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series
por: Weinstock, Leonard B., et al.
Publicado: (2022)

A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms
por: Molderings, Gerhard J., et al.
Publicado: (2023)

Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
por: Molderings, Gerhard J, et al.
Publicado: (2011)

Post-HPV-Vaccination Mast Cell Activation Syndrome: Possible Vaccine-Triggered Escalation of Undiagnosed Pre-Existing Mast Cell Disease?
por: Afrin, Lawrence B., et al.
Publicado: (2022)

Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA
por: Molderings, Gerhard J., et al.
Publicado: (2017)

Mast cell deposition and activation may be a new explanation for epiploic appendagitis
por: Weinstock, Leonard B., et al.
Publicado: (2018)

Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis
por: Seidel, Holger, et al.
Publicado: (2021)

Pharmacological treatment options for mast cell activation disease
por: Molderings, Gerhard J., et al.
Publicado: (2016)

Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
por: Weinstock, Leonard B, et al.
Publicado: (2018)

Utility of hydroxyurea in mast cell activation syndrome
por: Afrin, Lawrence B
Publicado: (2013)

White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome
por: Haenisch, B, et al.
Publicado: (2018)

Mast Cell Activation Syndrome as a Significant Comorbidity in Sickle Cell Disease
por: Afrin, Lawrence B.
Publicado: (2014)

Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness
por: Molderings, G. J., et al.
Publicado: (2020)

Familial Occurrence of Systemic Mast Cell Activation Disease
por: Molderings, Gerhard J., et al.
Publicado: (2013)

Case Report: Treatment of systemic mastocytosis with sunitinib
por: Molderings, Gerhard J., et al.
Publicado: (2017)

Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series
por: Weinstock, Leonard B., et al.
Publicado: (2023)

Chemical Intolerance and Mast Cell Activation: A Suspicious Synchronicity
por: Palmer, Raymond F., et al.
Publicado: (2023)

Mast Cell-Mediated Mechanisms of Nociception
por: Aich, Anupam, et al.
Publicado: (2015)

Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome
por: Schmidt, Tobias Jürgen, et al.
Publicado: (2022)

Correction : Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome
por: Schmidt, Tobias Jürgen, et al.
Publicado: (2023)

Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease
por: Vysniauskaite, Milda, et al.
Publicado: (2015)

Prostaglandin D(2)-supplemented “functional eicosanoid testing and typing” assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study
por: Schäfer, Dirk, et al.
Publicado: (2014)

Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation
por: Salvucci, Fabrizio, et al.
Publicado: (2023)

The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions
por: Yousefi, Omid Sascha, et al.
Publicado: (2013)

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021)

Immunological dysfunction and mast cell activation syndrome in long COVID
por: Sumantri, Stevent, et al.
Publicado: (2023)

Restless Legs Syndrome Shows Increased Silent Postmortem Cerebral Microvascular Disease With Gliosis
por: Walters, Arthur S., et al.
Publicado: (2021)

Mast cell activation is associated with post‐acute COVID‐19 syndrome
por: Wechsler, Joshua B., et al.
Publicado: (2021)

Prevalence and risk factors for mast cell tumours in dogs in England
por: Shoop, Stephanie JW, et al.
Publicado: (2015)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

Explanation for the signs and symptoms of tooth eruption: mast cells
por: Franzolin, Solange de Oliveira Braga, et al.
Publicado: (2019)

Mast cell glycosaminoglycans
por: Mulloy, B., et al.
Publicado: (2016)

Acupoint Activation: Response in Microcirculation and the Role of Mast Cells
por: Wang, Guangjun, et al.
Publicado: (2014)

Divergent Mast Cell Responses Modulate Antiviral Immunity During Influenza Virus Infection
por: Murphy-Schafer, Ashleigh R., et al.
Publicado: (2021)

Leukotrienes, mast cells, and T cells
por: McInnes, Iain B
Publicado: (2003)

Prevalence and Correlates of Long COVID Symptoms Among US Adults
por: Perlis, Roy H., et al.
Publicado: (2022)

Mast cell activation syndrome
por: Ratner, Vicki
Publicado: (2015)

Mast Cell Activation Disorders
por: Giannetti, Arianna, et al.
Publicado: (2021)

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
por: Rama, Tiago Azenha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_35arjjm30rgd8epr22ufsu5igb